Login
Home
Charts
Search
Watchlist
Products

Indo US Bio-Tech Ltd

INDOUS·BSE
77.200.00%Mon, 21 Sept '26

Indo US Bio-Tech Ltd

INDOUS
BSE
77.20
0.00%
|Mon, 21 Sept '26
SOICxStockScans Reports
6M
Price
Charts
Documents

Quick Ratios

Edit Ratios
Mkt Cap
Market Capitalization
155Cr
Close
Close Price
77.20
Industry
Industry
Seeds/Tissue Culture/Bio Technology
PE
Price To Earnings
13.54
PS
Price To Sales
1.37
Revenue
Revenue
113Cr
Rev Gr TTM
Revenue Growth TTM
2.53%
PAT Gr TTM
PAT Growth TTM
-35.58%

Quarterly Results

Consolidated
Standalone
Numbers
Percentage
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
162216252224333131232633
Growth YoY
Revenue Growth YoY%
15.042.6-12.929.140.26.6111.724.539.1-3.2-22.17.2
Expenses
ExpensesCr
131815211718292527192329
Operating Profit
Operating ProfitCr
341456554434
OPM
OPM%
16.419.26.214.923.123.513.717.813.518.212.412.0
Other Income
Other IncomeCr
000000000000
Interest Expense
Interest ExpenseCr
000010000111
Depreciation
DepreciationCr
000000100000
PBT
PBTCr
241345454323
Tax
TaxCr
000000000000
PAT
PATCr
241345453323
Growth YoY
PAT Growth YoY%
28.5168.6-81.233.8161.137.2607.748.3-20.9-40.6-46.5-35.3
NPM
NPM%
10.616.63.312.819.721.411.015.311.213.27.69.2
EPS
EPS
0.81.80.31.62.22.51.92.41.71.51.01.5
QuarterSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue
RevenueCr
162216252224333131232633
Growth YoY
Revenue Growth YoY%
15.042.6-12.929.140.26.6111.724.539.1-3.2-22.17.2
Expenses
ExpensesCr
131815211718292527192329
Operating Profit
Operating ProfitCr
341456554434
OPM
OPM%
16.419.26.214.923.123.513.717.813.518.212.412.0
Other Income
Other IncomeCr
000000000000
Interest Expense
Interest ExpenseCr
000010000111
Depreciation
DepreciationCr
000000100000
PBT
PBTCr
241345454323
Tax
TaxCr
000000000000
PAT
PATCr
241345453323
Growth YoY
PAT Growth YoY%
28.5168.6-81.233.8161.137.2607.748.3-20.9-40.6-46.5-35.3
NPM
NPM%
10.616.63.312.819.721.411.015.311.213.27.69.2
EPS
EPS
0.81.80.31.62.22.51.92.41.71.51.01.5

Profit & Loss

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
192529354040506273104110113
Growth
Revenue Growth%
-2.628.719.920.212.50.824.923.418.042.66.42.5
Expenses
ExpensesCr
192327323635435262859397
Operating Profit
Operating ProfitCr
1133467911191716
OPM
OPM%
2.75.19.29.79.913.813.815.214.818.215.413.8
Other Income
Other IncomeCr
0000000000
Interest Expense
Interest ExpenseCr
011011112123
Depreciation
DepreciationCr
000000011111
PBT
PBTCr
012334579171412
Tax
TaxCr
00110-1001011
PAT
PATCr
001235578161311
Growth
PAT Growth%
19.410.0265.844.121.4101.12.738.313.897.4-19.4-35.6
NPM
NPM%
1.91.64.95.96.412.710.511.711.315.711.910.2
EPS
EPS
2.74.21.51.73.52.93.84.18.16.55.7
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Revenue
RevenueCr
192529354040506273104110113
Growth
Revenue Growth%
-2.628.719.920.212.50.824.923.418.042.66.42.5
Expenses
ExpensesCr
192327323635435262859397
Operating Profit
Operating ProfitCr
1133467911191716
OPM
OPM%
2.75.19.29.79.913.813.815.214.818.215.413.8
Other Income
Other IncomeCr
0000000000
Interest Expense
Interest ExpenseCr
011011112123
Depreciation
DepreciationCr
000000011111
PBT
PBTCr
012334579171412
Tax
TaxCr
00110-1001011
PAT
PATCr
001235578161311
Growth
PAT Growth%
19.410.0265.844.121.4101.12.738.313.897.4-19.4-35.6
NPM
NPM%
1.91.64.95.96.412.710.511.711.315.711.910.2
EPS
EPS
2.74.21.51.73.52.93.84.18.16.55.7

Balance Sheet

Consolidated
Standalone
Numbers
Percentage
Financial YearMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
13566910202020
Reserves
ReservesCr
22910153044435872
Current Liabilities
Current LiabilitiesCr
910917181212191640
Non Current Liabilities
Non Current LiabilitiesCr
0212443331
Total Liabilities
Total LiabilitiesCr
131724354456698498133
Current Assets
Current AssetsCr
111521323847607387121
Non Current Assets
Non Current AssetsCr
22336910111112
Total Assets
Total AssetsCr
131724354456698498133
Financial YearMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
Equity CapitalCr
13566910202020
Reserves
ReservesCr
22910153044435872
Current Liabilities
Current LiabilitiesCr
910917181212191640
Non Current Liabilities
Non Current LiabilitiesCr
0212443331
Total Liabilities
Total LiabilitiesCr
131724354456698498133
Current Assets
Current AssetsCr
111521323847607387121
Non Current Assets
Non Current AssetsCr
22336910111112
Total Assets
Total AssetsCr
131724354456698498133

Cash Flow

Consolidated
Standalone
Financial YearMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
-1-3-103121-13
Investing Cash Flow
Investing Cash FlowCr
0-3-1-2-5-7-3-1-2
Financing Cash Flow
Financing Cash FlowCr
1621261-120
Net Cash Flow
Net Cash FlowCr
0000001-16
Free Cash Flow
Free Cash FlowCr
-1-4-1-2-1-101
CFO To PAT
CFO To PAT%
-60.9-151.8-33.34.455.57.327.08.7-95.9
CFO To EBITDA
CFO To EBITDA%
-32.5-92.3-21.44.142.05.620.67.5-74.0
Financial YearMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating Cash Flow
Operating Cash FlowCr
-1-3-103121-13
Investing Cash Flow
Investing Cash FlowCr
0-3-1-2-5-7-3-1-2
Financing Cash Flow
Financing Cash FlowCr
1621261-120
Net Cash Flow
Net Cash FlowCr
0000001-16
Free Cash Flow
Free Cash FlowCr
-1-4-1-2-1-101
CFO To PAT
CFO To PAT%
-60.9-151.8-33.34.455.57.327.08.7-95.9
CFO To EBITDA
CFO To EBITDA%
-32.5-92.3-21.44.142.05.620.67.5-74.0

Ratios

Consolidated
Standalone
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
51312062213445295196155
Price To Earnings
Price To Earnings
24.412.33.911.829.454.018.215.013.5
Price To Sales
Price To Sales
1.40.80.51.23.56.12.81.81.4
Price To Book
Price To Book
3.71.90.91.63.97.13.82.11.7
EV To EBITDA
EV To EBITDA
16.49.85.610.723.942.516.413.412.1
Profitability Ratios
Profitability Ratios
GPM
GPM%
14.016.120.118.631.726.225.527.828.1
OPM
OPM%
2.75.19.29.79.913.813.815.214.818.215.413.8
NPM
NPM%
1.91.64.95.96.412.710.511.711.315.711.910.2
ROCE
ROCE%
13.924.716.515.316.013.013.013.419.312.512.5
ROE
ROE%
11.329.315.015.423.713.513.313.120.714.214.2
ROA
ROA%
3.28.48.87.311.79.410.49.816.69.99.9
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Financial YearMar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026Current
Valuation Ratios
Valuation Ratios
Market Cap
Market CapitalizationCr
51312062213445295196155
Price To Earnings
Price To Earnings
24.412.33.911.829.454.018.215.013.5
Price To Sales
Price To Sales
1.40.80.51.23.56.12.81.81.4
Price To Book
Price To Book
3.71.90.91.63.97.13.82.11.7
EV To EBITDA
EV To EBITDA
16.49.85.610.723.942.516.413.412.1
Profitability Ratios
Profitability Ratios
GPM
GPM%
14.016.120.118.631.726.225.527.828.1
OPM
OPM%
2.75.19.29.79.913.813.815.214.818.215.413.8
NPM
NPM%
1.91.64.95.96.412.710.511.711.315.711.910.2
ROCE
ROCE%
13.924.716.515.316.013.013.013.419.312.512.5
ROE
ROE%
11.329.315.015.423.713.513.313.120.714.214.2
ROA
ROA%
3.28.48.87.311.79.410.49.816.69.99.9
Operational Ratios
Operational Ratios
Solvency Ratios
Solvency Ratios
Liquidity Ratios
Liquidity Ratios
Indo US Bio-Tech is an Indian seed company that invents, grows, and sells the genetic starting point for a farmer’s entire harvest - the seed itself. Founded in 2004 as a small private venture and now listed on India’s main stock exchanges, it has spent two decades building a research-first operation that breeds high-yielding hybrid and open-pollinated seeds for vegetables, field crops, and spices. The recurring approach is to own the full chain from laboratory to farm gate: it develops proprietary varieties using one of the country’s largest germplasm banks, multiplies them on its own farms and through contract growers, processes them in its own plants, and then sells them through a network of over 5,500 dealers and direct government contracts. # Business segments A single integrated engine - a seed research, production, and distribution company - where the same R&D, processing plants, and dealer network deliver every product category, from cotton to cumin to tomato. ## 1. Hybrid and varietal seeds: the genetic blueprint sold to farmers **The company makes money through a one-time sale of seeds - but the real asset is the germplasm library and breeding programme that creates varieties farmers will pay a premium for because they deliver higher yields or resist pests.** - **One of India’s largest germplasm collections** - the company holds a vast bank of crop genetic material, which is the raw ingredient its breeders use to develop new hybrids with better yield, disease resistance, and climate tolerance than what farmers currently plant. - **In-house R&D with government recognition** - its DSIR-recognised research centre employs plant breeders, biotechnologists, and agronomists who use molecular breeding and marker-assisted selection to create superior seeds, so new products emerge from its own labs rather than being licensed from others. - **A portfolio that spans the Indian plate** - the product range covers vegetable seeds (tomato, okra, brinjal, chilli, and more), field crops (cotton, wheat, maize, paddy), spices (cumin), oilseeds (mustard, groundnut), and pulses, which means the company is not dependent on any single crop or season. - **Proven hits that last** - two hybrid cotton varieties launched in 2010 and 2011, Indo US 955 and Indo US 927, still command sizable market share, demonstrating that a successful genetic product can generate sales for well over a decade. - **Partnerships with government labs** - the company produces and markets specific varieties developed by ICAR, IARI, and DOGR (such as maize hybrids DMRH 1301 and PUSA HQPM-1, and onion varieties Bhima Super and Bhima Red), giving it access to publicly funded research that it commercialises through its own distribution network. ## 2. Seed production and processing: the factory that turns research into inventory **The company owns the physical infrastructure - processing plants, cold storage, and India’s second seed testing laboratory - that transforms breeder seed into millions of packets ready for sale, with quality control at every step.** - **Own processing plants in Gujarat** - seeds are cleaned, graded, sorted, and packed using gravity separators and automatic coating and pouch-filling machines, so the company controls the speed and quality of output rather than relying on third-party processors. - **India’s second seed testing laboratory** - the company operates a fully equipped lab (the first of its kind in Gujarat) that tests every lot for physical purity, genetic purity, and germination potential against the standards of the Indian Seed Act, which is how it guarantees that what is on the label is what is in the packet. - **Cold storage and contract facilities** - temperature- and humidity-controlled storage preserves seed viability between seasons, and the company also hires custom processing and storage capacity in other states to ensure timely supply across the country. - **Field trials before sale** - dedicated demonstration plots test variety performance under real-world conditions, so the company can show farmers exactly how a seed will behave in their soil and climate before they buy. ## 3. Distribution and go-to-market: the last mile to the farmer **A pan-India network of over 5,500 active dealers, combined with direct government rate contracts and an export channel, places the company’s seeds in front of farmers across multiple states and countries.** - **Over 5,500 dealers across India** - the distribution network has more than doubled from earlier years and now reaches farmers in Gujarat, Maharashtra, Madhya Pradesh, Rajasthan, Punjab, Uttar Pradesh, Bihar, Karnataka, and other states, supported by distribution centres that ensure timely delivery. - **Government contracts provide a stable demand base** - the company holds rate contracts to supply seeds to the governments of Madhya Pradesh and Chhattisgarh, as well as to NAFED and state seed corporations, which means a portion of its sales is secured through public procurement rather than purely discretionary farmer purchases. - **Farmer education as a sales tool** - the company runs field demonstrations and provides hands-on guidance to farmers, showing them how to cultivate crops for better yields, which builds trust in the “INDO US” brand and drives repeat purchases. - **Exports to multiple continents** - seeds are sold to buyers in the USA, Kuwait, Sri Lanka, Mauritius, Cameroon, and other countries, and the company actively participates in events like the APSA Seed Congress 2025 in Mumbai to find new export opportunities. # Group structure and partners **The company operates as a standalone entity with no subsidiaries, but it is closely held by its founding family and anchored by research partnerships with India’s top agricultural institutions.** - **No subsidiaries or joint ventures** - as of the latest filings, Indo US Bio-Tech has no subsidiary companies, having sold its only non-operational subsidiary (Agripari E-Commerce) to a promoter group member in 2022 at face value. - **Founder-led with promoter entities** - the Managing Director, Jagdish Ajudia, founded the company and leads a board that includes two other executive promoter directors; a related promoter entity, Indo US Agriseeds Limited, held roughly 8.8% of voting capital after a series of open-market sales in early 2026 (D1 p.40, D15-D20). - **Institutional MOUs for variety access** - the company has formal agreements with ICAR, IARI, MPUAT, DOGR, and NAU to produce and market specific seed varieties, and with NSC, NHRDF, and HIL India for seed supply and joint commercialisation, effectively expanding its product catalogue through partnerships rather than only internal R&D.

Documents — Indo US Bio-Tech Ltd

  • Q1 FY2027 Quarterly Result (Jun 2026, PDF): https://www.stockscans.in/document/lln2wey51dwyjwg0mg4cbt6n.pdf
  • Q4 FY2026 Quarterly Result (Mar 2026, PDF): https://www.stockscans.in/document/4cf8thr7k7ha39y2ap9kdvgo.pdf
  • Q3 FY2026 Quarterly Result (Dec 2025, PDF): https://www.stockscans.in/document/5rbn27oh92l1fpygappbrmku.pdf
  • Q4 FY2025 Quarterly Result (Mar 2025, PDF): https://www.stockscans.in/document/t2k7q6av14qobfh6tgkw51it.pdf
  • Q3 FY2025 Quarterly Result (Dec 2024, PDF): https://www.stockscans.in/document/4lifturwurhsvgpaoacl4pww.pdf
  • Q2 FY2025 Quarterly Result (Sep 2024, PDF): https://www.stockscans.in/document/3ky9i87d8onrzym93u7f6ab6.pdf
  • Q4 FY2024 Quarterly Result (Mar 2024, PDF): https://www.stockscans.in/document/cetssrlgmpnzlnjocnqjg4w2.pdf
  • Q3 FY2024 Quarterly Result (Dec 2023, PDF): https://www.stockscans.in/document/w3kmy65a6294mdu25or8msik.pdf
  • FY2026 Annual Report (PDF): https://www.stockscans.in/document/jxfrqso1mjildrng00hwa1ym.pdf
  • FY2025 Annual Report (PDF): https://www.stockscans.in/document/r3lodoce63oiehl5tczdvt5f.pdf
  • FY2024 Annual Report (PDF): https://www.stockscans.in/document/08lnsbmxtujh5h4omdtrpjuo.pdf
  • FY2023 Annual Report (PDF): https://www.stockscans.in/document/izzio4fyew3l9010pz32amis.pdf
  • FY2022 Annual Report (PDF): https://www.stockscans.in/document/na0r1rjyod4ypcy78ilrcl5e.pdf
  • FY2021 Annual Report (PDF): https://www.stockscans.in/document/cmatst5v04p78arwlrbyenhc.pdf
  • FY2020 Annual Report (PDF): https://www.stockscans.in/document/9kmft2auuhj2tfok84j4n7u2.pdf